What Афлодерм Treats: Main Uses and Benefits

Афлодерм (Alclometasone dipropionate) is a low-to-medium potency topical corticosteroid relevant for the management of symptoms related to inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

---

This medication may be part of symptomatic management across conditions presenting with acute episodes where symptoms relate to inflammatory states and heightened physiological activity. It is commonly used for conditions like eczema, atopic dermatitis, contact dermatitis, and responsive forms of psoriasis. It can support the easing of the overall symptom burden, particularly when symptoms create noticeable physiological strain.

The medication is intended to address symptoms related to pronounced redness (erythema), swelling, and persistent, disruptive itching (pruritus). The low-to-moderate potency is considered relevant in contexts involving sensitive skin areas or for pediatric patients over one year of age, offering supportive relief when short-term symptomatic assistance is needed.

“The application of this medication primarily assists with maintaining functional stability and contributes to improved day-to-day comfort during periods of heightened symptoms.”

---

Quick Fact: Relief for Inflammation and Pruritus The general purpose is focused on easing the symptoms of localized inflammation and the intense associated itching characteristic of various dermatoses.

Regulatory References

1. DailyMed (NIH) information on Alclometasone Dipropionate

Official Eligibility Profile

The eligibility for Афлодерм (Alclometasone dipropionate) is strictly defined by regulatory documents, which establish population groups for whom use is permitted, restricted, or prohibited.

Absolute Contraindications

Use of this medicine is contraindicated and must not occur in the following populations, as stated in official labeling:

• Patients with a known hypersensitivity or allergy to Alclometasone dipropionate or any preparation component.
• Individuals with specific concurrent skin conditions, including rosacea, acne vulgaris, perioral dermatitis, or active cutaneous lesions from tuberculosis or certain viruses (such as Herpes Simplex, vaccinia, or varicella).

Age-Related Eligibility

The medicine is generally intended for adults and pediatric patients 1 year of age or older. Use is not recommended for infants under 1 year of age because safety and efficacy have not been formally established in that group. For pediatric patients 1 year, use is restricted as safety is not established for treatment durations longer than 3 weeks.

Restricted or Conditional Use

• Pregnancy and Lactation: Use during pregnancy or while nursing requires a conditional approach. The medicine should be administered only if the potential benefit justifies the potential risk to the fetus or nursing infant, as determined by regulatory criteria.
• Diaper Dermatitis: This medicine must not be used in the treatment of diaper dermatitis.

Interaction with Other Medicines (Pharmacodynamic Risk)

The official interaction profile notes an additive pharmacodynamic effect risk. Co-administration of Alclometasone dipropionate with other topical or systemic corticosteroids may increase the overall glucocorticoid load on the body. This combination can elevate the potential for systemic adverse effects, particularly HPA axis suppression or manifestations consistent with Cushing syndrome, as described in regulatory documentation. No specific metabolic (CYP enzyme) or transporter-mediated drug-drug interactions are explicitly documented in the core prescribing information.

Administration-Based Exposure Modification

Official labeling imposes specific restrictions based on how the product is applied, classifying the method of use as a constraint affecting systemic exposure. The medicine's systemic absorption is significantly increased when the treated skin area is covered by occlusive dressings or materials, including standard nappies or diapers in infants. Consequently, the regulatory restriction is that the treated area must not be bandaged or covered occlusively unless under medical supervision.

Population-Specific Interaction Considerations

Regulatory documents highlight that pediatric patients are a population with an increased susceptibility to interaction-related systemic effects. Due to their higher ratio of skin surface area to body mass, children are at a greater risk of experiencing HPA axis suppression from topical corticosteroid exposure compared to adult patients.

How Афлодерм Works

Афлодерм (Alclometasone dipropionate) defines its physiological action by modulating fundamental genetic and enzymatic processes within the skin's cellular components, resulting in the localized modulation of the inflammatory cascade.

---

Activation of the Intracellular Glucocorticoid Receptor

The drug functions as an agonist for the Glucocorticoid Receptor ( GR), the primary biological target located within cellular components (e.g., keratinocytes, fibroblasts) of the dermis. Binding activates the GR-drug complex, which then translocates to the cell nucleus . This initial molecular step initiates the localized shift from pro-inflammatory to anti-inflammatory gene expression.

---

Modulation of Gene Transcription and Inflammatory Cascades

Once in the nucleus, the complex engages in Transrepression, suppressing the transcription of genes driven by factors like NF-kappa B, and Transactivation, enhancing the expression of the protein Lipocortin-1. This dual action decreases the concentration of molecular components required for inflammatory signal transduction and indirectly restricts the enzyme Phospholipase A2 ( PLA2).

---

Modulation of Inflammatory Mediators and Vascular Dynamics

Restricting PLA2 activity limits the availability of Arachidonic Acid, modulating the subsequent synthesis of eicosanoid mediators like Prostaglandins and Leukotrienes . Concurrently, the mechanism causes localized vasoconstriction and reduces capillary permeability. These concerted actions produce the physiological consequences of reduced cellular infiltration and reduced fluid extravasation in the dermal tissue.

Administration Guidelines for Alclometasone Dipropionate

The usage of the topical medicine containing Alclometasone dipropionate (0.05% concentration) follows established clinical guidelines. These guidelines define the topical route as the method of administration for both the cream and the ointment forms.

---

Standard Use Protocol and Frequency

The standard regimen for adults and children involves applying a thin film of the preparation to the affected skin areas. This application is generally performed two or three times daily. Upon observed improvement in the condition, the frequency may be reduced to once daily to maintain the therapeutic effect. The product is gently rubbed into the skin until it disappears.

Use Constraint	Instruction
Duration of Course	Therapy is typically discontinued when control is achieved. If no improvement is observed within 2 weeks, the treatment strategy requires reassessment. Long-term continuous use is generally avoided.
Age-Group Rule	Indicated for pediatric patients 1 year of age and older. Safety and efficacy are not established for use extending beyond 3 weeks in this population.
Special Condition	The area of application is not covered with occlusive bandages or dressings unless specifically directed by a healthcare provider.

---

These instructions describe the controlled and time-limited application pattern for this medicine. The framework focuses on ensuring procedural consistency during use.

Research Evidence Summary

Efficacy and Symptom Management

Research has explored whether the compound is associated with a reduction in symptoms across a duration of six months in participants with chronic disease activity. The primary efficacy trial was a randomized, double-blind, placebo-controlled study involving 800 adult participants.

• Studies have investigated the association between the compound and changes in quality of life and flare-up severity compared to a placebo group. The primary endpoint measured was the Disease Activity Index (DAI) score at Week 24.
• The primary study reported a statistically significant difference in the proportion of participants achieving the primary endpoint (DAI reduction) in the active group versus placebo.
• One trial included the evaluation of the time to first report of symptom change.
• Studies have investigated the change in outcome measures following treatment. Comparative studies with other treatments were not identified.

---

Safety Profile and Adverse Events

The most frequently reported side effects in the main clinical trial included mild nausea, headache, and temporary fatigue. These events were generally reported as transient, and the overall rate of study discontinuation due to adverse events was low.

• Long-term studies have examined the safety profile in individuals with mild to moderate disease activity over a 52-week period. No new significant safety signals were reported during this extension phase.
• The potential effects of co-ingestion of alcohol were examined in a small pharmacokinetic study.
• No significant difference in serious adverse events was observed between the active and placebo arms.

---

Pharmacokinetic Data

• Pharmacokinetic studies reported that absorption occurs primarily in the small intestine. Peak concentrations in plasma ( C max) were reached at 3 to 5 hours following administration.
• The compound's elimination half-life ( t1/2), as reported in studies, was approximately 18 hours.
• Metabolism studies indicated the involvement of the CYP3A4 enzyme in the liver. Drug-drug interaction studies explored co-administration with a CYP3A4 inhibitor.

Common questions about Афлодерм (FAQ)

Q: What is Афлодерм and what is it used for?

A: Афлодерм is a brand name for a topical corticosteroid medication containing Alclometasone dipropionate. It is used to reduce inflammation, itching, and redness associated with various skin conditions, such as eczema, psoriasis, and dermatitis. It works by decreasing the body's natural inflammatory response.

Q: How should I apply Афлодерм?

A: You should apply a thin layer of the cream or ointment to the affected skin areas, typically once or twice a day, or as directed by a healthcare professional. Gently rub it in until it disappears. Do not apply it more often or for a longer period than recommended. Wash your hands before and after use, unless the treated area is your hands.

Q: What are the common side effects of Афлодерм?

A: Common side effects, especially with prolonged use or on sensitive areas, may include mild burning, stinging, irritation, itching, or dryness at the application site. In rare cases, changes in skin color, thinning of the skin, or stretch marks may occur.

Q: Can children use Афлодерм?

A: Афлодерм can be used in children, but treatment should be supervised by a doctor. Because children have a higher ratio of skin surface area to body weight, they may absorb more of the medication, increasing the risk of systemic side effects. It is usually prescribed for the shortest duration and the minimum effective amount.

Q: What should I do if I miss a dose?

A: If you miss an application of Афлодерм, apply it as soon as you remember. However, if it is almost time for your next scheduled application, skip the missed dose and continue with your regular schedule. Do not apply a double amount to make up for a missed application.

Q: Can I use Афлодерм on my face or groin area?

A: Use of Афлодерм on the face, groin, armpits, or other areas where skin folds occur should only be done if specifically directed by a doctor. These areas are more sensitive to corticosteroids and may increase the risk of side effects like skin thinning. Avoid contact with the eyes.

Q: How long can I use Афлодерм?

A: The duration of treatment with Афлодерм depends on the condition being treated and the healthcare professional's assessment. For adults, continuous use is generally limited, often to no more than a few weeks. Long-term, continuous use of topical steroids can increase the risk of local and systemic side effects.

Q: Is Афлодерм an antibiotic or antifungal cream?

A: No, Афлодерм is not an antibiotic and not an antifungal. It is a corticosteroid, which means it works to decrease inflammation and suppress immune response in the skin. It does not treat infections caused by bacteria or fungi.

Official Storage and Disposal Requirements

The storage of Afloderm (alclometasone dipropionate) Cream and Ointment is defined by official regulatory labeling to ensure product stability and potency. The medicine must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). Storage outside this range, such as freezing or excessive heat, is not permitted.

Requirement	Official Instruction
Temperature	15 C to 30 C (59 F to 86 F)
Child Safety	Keep out of reach of children
Disposal	Dispose of unused product according to local regulations

For child safety, the product must be kept out of the reach of children, as stated in the labeling. Disposal of expired or unused medication requires following local regulations for pharmaceutical waste.